Virbac SA (Virbac) is a company that provides a comprehensive range of products and services for veterinarians, farmers, and pet owners in over 100 countries. The company focuses on animal health, offering solutions for diagnosing, preventing, and treating various animal diseases. Virbac serves industries related to animal health, including veterinary medicine, pet care, and livestock management.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Virbac’s research and development (R&D) initiatives concentrate on preventing, diagnosing, and treating pathologies across multiple species, using an innovation model that covers biologicals, pharmaceuticals, diagnostics, pet food, and pet care. The company prioritizes applied research and development, encouraging synergies between field teams and researchers, while sustaining partnerships with universities, research laboratories, and biotech companies. R&D activities are structured globally to support project development with a worldwide perspective, ensuring closeness to production centers and responsiveness to regional specificities in the livestock sector. Virbac SA’s R&D units operate on five continents, each with defined roles and responsibilities: France (Carros and Vauvert): Focus on biological and pharmaceutical projects for companion and farm animals, and pet food projects; Australia (Penrith & Milperra): Specializes in biological and pharmaceutical projects for ruminants; Mexico (Guadalajara): Develops pharmaceutical products for companion and farm animals; the US (St. Louis): Works on pharmaceutical products for companion and farm animals; Vietnam (Ho Chi Minh City): Focuses on pharmaceuticals and probiotics for farm and companion animals; Taiwan (Pingtung): Develops biological projects for farm animals; Chile (Santiago): Conducts biological and pharmaceutical projects for all animal species; Uruguay (Montevideo): Specializes in biological projects for ruminants; China (Jinan city): Develops pharmaceutical and non-pharmaceutical products; India (Hyderabad): Focuses on biological projects for poultry; and Japan (Tokyo and Kyoto): Develops pharmaceutical and biological products for major species. In FY2025, the company spent EUR26.5 million on R&D, which as a percentage of revenue, stood at 1.8% and increased 29.2% YoY.